RÉSUMÉ
As described throughout this book, different triggers can elicit a variety of different cytokine storm disorders that share overlapping clinical features (Fig. 31.1). Even within a particular cytokine storm disorder, multiple different triggers can elicit the syndrome. Like HLH, multicentric Castleman disease (MCD) serves as a great example of this as it can be caused by a viral infection, neoplastic cell population, or an unknown cause. Furthermore, the idiopathic subtype of MCD (iMCD) provides one of the first examples of a cytokine storm disorder that could be abrogated with targeted neutralization of a single cytokine when inhibition with the anti-interleukin-6 (IL-6) receptor monoclonal antibody tocilizumab was shown to effectively treat iMCD in the 1990s. Of course, this "iMCD treatment," tocilizumab, has been used in a variety of cytokine storm settings over the last 30+ years.
Sujet(s)
Anticorps monoclonaux humanisés , Hyperplasie lymphoïde angiofolliculaire , Syndrome de libération de cytokines , Hyperplasie lymphoïde angiofolliculaire/traitement médicamenteux , Hyperplasie lymphoïde angiofolliculaire/immunologie , Hyperplasie lymphoïde angiofolliculaire/anatomopathologie , Humains , Syndrome de libération de cytokines/immunologie , Syndrome de libération de cytokines/traitement médicamenteux , Syndrome de libération de cytokines/étiologie , Anticorps monoclonaux humanisés/usage thérapeutique , Cytokines/métabolisme , Interleukine-6/immunologie , Interleukine-6/métabolisme , Interleukine-6/antagonistes et inhibiteurs , Récepteurs à l'interleukine-6/antagonistes et inhibiteurs , Récepteurs à l'interleukine-6/immunologieRÉSUMÉ
Interleukin-6 (IL-6) is a pro-inflammatory cytokine elevated in cytokine storm syndromes, including hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). It is also elevated in cytokine release syndrome (CRS) after immune activating cancer therapies such as chimeric antigen receptor (CAR) T-cells or bispecific T-cell engagers (BITEs) and in some patients after infection with SARS-CoV-2. The interaction of IL-6 with its receptor complex can happen in several forms, making effectively blocking this cytokine's effects clinically challenging. Fortunately, effective clinical agents targeting the IL-6 receptor (tocilizumab) and IL-6 directly (siltuximab) have been developed and are approved for use in humans. IL-6 blockade has now been used to safely and effectively treat several cytokine storm syndromes (CSS). Other methods of investigation in effective IL-6 blockade are underway.
Sujet(s)
Anticorps monoclonaux humanisés , COVID-19 , Syndrome de libération de cytokines , Interleukine-6 , Récepteurs à l'interleukine-6 , Humains , Syndrome de libération de cytokines/immunologie , Syndrome de libération de cytokines/traitement médicamenteux , Interleukine-6/antagonistes et inhibiteurs , Interleukine-6/immunologie , Interleukine-6/métabolisme , Anticorps monoclonaux humanisés/usage thérapeutique , COVID-19/immunologie , Récepteurs à l'interleukine-6/antagonistes et inhibiteurs , Récepteurs à l'interleukine-6/immunologie , SARS-CoV-2/immunologie , Lymphohistiocytose hémophagocytaire/immunologie , Lymphohistiocytose hémophagocytaire/traitement médicamenteux , Anticorps monoclonaux/usage thérapeutique , Syndrome d'activation macrophagique/immunologie , Syndrome d'activation macrophagique/traitement médicamenteuxRÉSUMÉ
Like TNFα, IL-6 is upregulated in Crohn's disease (CD) especially in patients associated with Mycobacterium avium paratuberculosis (MAP) infection, and both cytokines have been targeted as a therapeutic option for the treatment of the disease despite the accepted partial response in some patients. Limited response to anti-IL-6 receptor-neutralizing antibodies therapy may be related to the homeostatic dual role of IL-6. In this study, we investigated the effects and the signaling mechanism of IL-6 involved in intestinal epithelial integrity and function during MAP infection using an in vitro model that consists of THP-1, HT-29 and Caco-2 cell lines. Clinically, we determined that plasma samples from MAP-infected CD patients have higher IL-6 levels compared to controls (P-value < 0.001). In CD-like macrophages, MAP infection has significantly upregulated the secretion of IL-6 and the shedding of (IL-6R) from THP-1 macrophages, P-value < 0.05. Intestinal cell lines (Caco-2 and HT-29) were treated with the supernatant of MAP-infected THP-1 macrophages with or without a neutralizing anti-IL-6R antibody. Treating intestinal Caco-2 cells with supernatant of MAP-infected macrophages resulted in significant upregulation of intestinal damage markers including claudin-2 and SERPINE1/PAI-1. Interestingly, blocking IL-6 signaling exacerbated that damage and further increased the levels of the damage markers. In HT-29 cells, MAP infection upregulated MUC2 expression, a protective response that was reversed when IL-6R was neutralized. More importantly, blocking IL-6 signaling during MAP infection rescued damaged Caco-2 cells from MAP-induced apoptosis. The data clearly supports a protective role of IL-6 in intestinal epithelia integrity and function especially in CD patients associated with MAP infection. The findings may explain the ineffective response to anti-IL6 based therapy and strongly support a therapeutic option that restores the physiologic level of IL-6 in patient's plasma. A new treatment strategy based on attenuation of IL-6 expression and secretion in inflammatory diseases should be considered.
Sujet(s)
Interleukine-6 , Muqueuse intestinale , Mycobacterium avium ssp. paratuberculosis , Paratuberculose , Récepteurs à l'interleukine-6 , Humains , Récepteurs à l'interleukine-6/métabolisme , Récepteurs à l'interleukine-6/antagonistes et inhibiteurs , Récepteurs à l'interleukine-6/immunologie , Mycobacterium avium ssp. paratuberculosis/immunologie , Cellules Caco-2 , Interleukine-6/métabolisme , Interleukine-6/immunologie , Cellules HT29 , Muqueuse intestinale/microbiologie , Muqueuse intestinale/immunologie , Muqueuse intestinale/métabolisme , Muqueuse intestinale/anatomopathologie , Paratuberculose/immunologie , Paratuberculose/microbiologie , Macrophages/immunologie , Macrophages/métabolisme , Macrophages/microbiologie , Maladie de Crohn/immunologie , Maladie de Crohn/microbiologie , Cellules THP-1 , Mâle , Anticorps neutralisants/pharmacologie , Femelle , Adulte , Cellules épithéliales/métabolisme , Cellules épithéliales/immunologie , Cellules épithéliales/microbiologie , Adulte d'âge moyen , Transduction du signalRÉSUMÉ
BACKGROUND: A cost-effective Escherichia coli expression system has gained popularity for producing virus-like particle (VLP) vaccines. However, the challenge lies in balancing the endotoxin residue and removal costs, as residual endotoxins can cause inflammatory reactions in the body. RESULTS: In this study, porcine parvovirus virus-like particles (PPV-VLPs) were successfully assembled from Decreased Endotoxic BL21 (BL21-DeE), and the effect of structural changes in the lipid A of BL21 on endotoxin activity, immunogenicity, and safety was investigated. The lipopolysaccharide purified from BL21-DeE produced lower IL-6 and TNF-α than that from wild-type BL21 (BL21-W) in both RAW264.7 cells and BALB/c mice. Additionally, mice immunized with PPV-VLP derived form BL21-DeE (BL21-DeE-VLP) showed significantly lower production of inflammatory factors and a smaller increase in body temperature within 3 h than those immunized with VLP from BL21-W (BL21-W-VLP) and endotoxin-removed VLP (ReE-VLP). Moreover, mice in the BL21-DeE-VLP immunized group had similar levels of serum antibodies as those in the BL21-W-VLP group but significantly higher levels than those in the ReE-VLP group. Furthermore, the liver, lungs, and kidneys showed no pathological damage compared with the BL21-W-VLP group. CONCLUSION: Overall, this study proposes a method for producing VLP with high immunogenicity and minimal endotoxin activity without chemical or physical endotoxin removal methods. This method could address the issue of endotoxin residues in the VLP and provide production benefits.
Sujet(s)
Endotoxines , Escherichia coli , Lipide A , Souris de lignée BALB C , Parvovirus porcin , Vaccins à pseudo-particules virales , Animaux , Souris , Escherichia coli/génétique , Escherichia coli/métabolisme , Parvovirus porcin/immunologie , Parvovirus porcin/génétique , Vaccins à pseudo-particules virales/immunologie , Endotoxines/immunologie , Cellules RAW 264.7 , Lipide A/immunologie , Lipide A/analogues et dérivés , Interleukine-6/immunologie , Facteur de nécrose tumorale alpha/métabolisme , Femelle , Suidae , Lipopolysaccharides/immunologieRÉSUMÉ
Infections and neurodegenerative diseases induce neuroinflammation, but affected individuals often show nonneural symptoms including muscle pain and muscle fatigue. The molecular pathways by which neuroinflammation causes pathologies outside the central nervous system (CNS) are poorly understood. We developed multiple models to investigate the impact of CNS stressors on motor function and found that Escherichia coli infections and SARS-CoV-2 protein expression caused reactive oxygen species (ROS) to accumulate in the brain. ROS induced expression of the cytokine Unpaired 3 (Upd3) in Drosophila and its ortholog, IL-6, in mice. CNS-derived Upd3/IL-6 activated the JAK-STAT pathway in skeletal muscle, which caused muscle mitochondrial dysfunction and impaired motor function. We observed similar phenotypes after expressing toxic amyloid-ß (Aß42) in the CNS. Infection and chronic disease therefore activate a systemic brain-muscle signaling axis in which CNS-derived cytokines bypass the connectome and directly regulate muscle physiology, highlighting IL-6 as a therapeutic target to treat disease-associated muscle dysfunction.
Sujet(s)
Encéphale , COVID-19 , Muscles squelettiques , Transduction du signal , Animaux , Encéphale/immunologie , Encéphale/métabolisme , Transduction du signal/immunologie , Souris , Muscles squelettiques/immunologie , Muscles squelettiques/métabolisme , COVID-19/immunologie , Maladie chronique , Interleukine-6/métabolisme , Interleukine-6/immunologie , Infections à Escherichia coli/immunologie , Espèces réactives de l'oxygène/métabolisme , Espèces réactives de l'oxygène/immunologie , Protéines de Drosophila/métabolisme , Protéines de Drosophila/immunologie , Protéines de Drosophila/génétique , SARS-CoV-2/immunologie , Drosophila melanogaster/immunologie , Peptides bêta-amyloïdes/métabolisme , Humains , Souris de lignée C57BLRÉSUMÉ
Recombinant adeno-associated virus (AAV) vectors have emerged as the preferred platform for gene therapy of rare human diseases. Despite the clinical promise, host immune responses to AAV vectors and transgene remain a major barrier to the development of successful AAV-based human gene therapies. Here, we assessed the human innate immune response to AAV9, the preferred serotype for AAV-mediated gene therapy of the CNS. We showed that AAV9 induced type I interferon (IFN) and IL-6 responses in human blood from healthy donors. This innate response was replicated with AAV6, required full viral particles, but was not observed in every donor. Depleting CpG motifs from the AAV transgene or inhibiting TLR9 signaling reduced type I IFN response to AAV9 in responding donors, highlighting the importance of TLR9-mediated DNA sensing for the innate response to AAV9. Remarkably, we further demonstrated that only seropositive donors with preexisting antibodies to AAV9 capsid mounted an innate immune response to AAV9 in human whole blood and that anti-AAV9 antibodies were necessary and sufficient to promote type I IFN release and plasmacytoid dendritic (pDC) cell activation in response to AAV9. Thus, our study reveals a previously unidentified requirement for AAV preexisting antibodies for TLR9-mediated type I IFN response to AAV9 in human blood.
Sujet(s)
Dependovirus , Vecteurs génétiques , Immunité humorale , Interféron de type I , Récepteur-9 de type Toll-like , Humains , Récepteur-9 de type Toll-like/immunologie , Récepteur-9 de type Toll-like/génétique , Dependovirus/génétique , Dependovirus/immunologie , Interféron de type I/immunologie , Vecteurs génétiques/génétique , Immunité innée , Cellules dendritiques/immunologie , Anticorps antiviraux/sang , Anticorps antiviraux/immunologie , Thérapie génétique , Interleukine-6/sang , Interleukine-6/immunologieRÉSUMÉ
Antibody-producing plasma cells fuel humoral immune responses. They also contribute to autoimmune diseases such as systemic lupus erythematosus or IgA nephropathy. Interleukin-6 and the tumor necrosis factor (TNF) family ligands BAFF (B cell-activating factor) and APRIL (a proliferation-inducing ligand) participate in plasma cell survival. BAFF binds to three receptors, BAFFR (BAFF receptor), TACI (transmembrane activator and CAML interactor), and BCMA (B cell maturation antigen), while APRIL binds to TACI, BCMA, and proteoglycans. However, which ligand-receptor pair(s) are required to maintain plasma cells in different body locations remains unknown. Here, by combining mouse genetic and pharmacological approaches, we found that plasma cells required BCMA and/or TACI but not BAFFR. BCMA responded exclusively to APRIL, while TACI responded to both BAFF and APRIL, identifying three self-sufficient ligand-receptor pairs for plasma cell maintenance: BAFF-TACI, APRIL-TACI, and APRIL-BCMA. Together, these actors accounted for 90% of circulating antibodies. In BAFF-ko mice, the reduction of plasma cells upon APRIL inhibition indicated that APRIL could function in the absence of BAFF-APRIL heteromers. No evidence was found that in the absence of BCMA and TACI, binding of APRIL to proteoglycans would help maintain plasma cells. IL-6, alone or together with BAFF and APRIL, supported mainly splenic plasmablasts and plasma cells and contributed to circulating IgG but not IgA levels. In conclusion, survival factors for plasma cells can vary with body location and with the antibody isotype that plasma cells produce. To efficiently target plasma cells, in particular IgA-producing ones, dual inhibition of BAFF and APRIL is required.
Sujet(s)
Facteur d'activation des lymphocytes B , Récepteur du BAFF , Antigène de maturation des cellules B , Interleukine-6 , Protéine TACI , Membre-13 de la superfamille du facteur de nécrose tumorale , Animaux , Facteur d'activation des lymphocytes B/immunologie , Facteur d'activation des lymphocytes B/métabolisme , Facteur d'activation des lymphocytes B/génétique , Membre-13 de la superfamille du facteur de nécrose tumorale/métabolisme , Membre-13 de la superfamille du facteur de nécrose tumorale/immunologie , Membre-13 de la superfamille du facteur de nécrose tumorale/génétique , Antigène de maturation des cellules B/immunologie , Antigène de maturation des cellules B/métabolisme , Protéine TACI/métabolisme , Protéine TACI/génétique , Protéine TACI/immunologie , Interleukine-6/métabolisme , Interleukine-6/immunologie , Souris , Récepteur du BAFF/métabolisme , Récepteur du BAFF/immunologie , Récepteur du BAFF/génétique , Plasmocytes/immunologie , Plasmocytes/métabolisme , Souris knockout , Cellules productrices d'anticorps/immunologie , Cellules productrices d'anticorps/métabolisme , Souris de lignée C57BLRÉSUMÉ
The synergistic effect and compatibility structure of active anti-inflammatory ingredients(iridoid glycosides: shanzhiside methylester and 8-O-acetylshanzhiside methyl ester, flavonoid glycoside: luteoloside, and phenylethanoid glycoside: forsythoside B) from Lamiophlomis rotata were explored based on network pharmacology and component structure theory. In network pharmacology, CTD, SwisseTargetPrediction, and PharmMapper databases were used to collect and screen the targets of all active ingredients. The inflammation-related targets were obtained from CTD and GeneCards databases. The core targets were obtained by Venny 2.1.0, STRING, and Cytoscape 3.9.1. Core targets were annotated by the GO function and enriched by the KEGG pathway based on the DAVID database. In terms of component structure, based on a uniform design method and xylene-induced ear swelling model in mice, tumor necrosis factor-α and interleukin-6 were taken as the dependent variables, and the compatibility relationship among anti-inflammatory ingredients from L. rotata was explored through the quadratic polynomial stepwise regression. In addition, in vivo pharmacological experiments were conducted to verify the results. A network pharmacology study showed that compared with a single ingredient, the combined action of the three ingredients can synergistically exert anti-inflammatory effects through more biological processes, pathways, and targets. Component structure study showed that the optimal structural ratio of shanzhiside methylester and 8-O-acetylshanzhiside methyl ester in the iridoid glycoside ingredient was 1.21â¶1. The optimal structural ratio among the three types of ingredients(iridoid glycosidesâ¶phenylethanol glycosideâ¶flavonoid glycoside) was 4.8â¶1.6â¶1. In conclusion, each anti-inflammatory ingredient from L. rotata can work synergistically, and there is an optimal compatibility ratio relationship among these ingredients. This work provides a new experimental basis for the intrinsic quality control of L. rotata.
Sujet(s)
Anti-inflammatoires , Médicaments issus de plantes chinoises , Pharmacologie des réseaux , Anti-inflammatoires/composition chimique , Anti-inflammatoires/pharmacologie , Animaux , Souris , Médicaments issus de plantes chinoises/composition chimique , Médicaments issus de plantes chinoises/pharmacologie , Mâle , Lamiaceae/composition chimique , Facteur de nécrose tumorale alpha/métabolisme , Facteur de nécrose tumorale alpha/immunologie , Synergie des médicaments , Interleukine-6/immunologie , Interleukine-6/métabolisme , Interleukine-6/génétiqueRÉSUMÉ
Aim: An assay to detect anti-tocilizumab antibodies in the presence of high levels of circulating target and drug is needed for immunogenicity assessment in comparative clinical studies.Methods: An assay was developed and validated using a combination of blocking agents and dilutions to overcome target interference challenges.Results: No false-positive signal was detected in serum samples spiked with 350-500 ng/ml of IL-6 receptor. As low as 50 ng/ml of positive control antibodies could be detected in the presence of either 500 ng/ml of IL-6 or 250 µg/ml of the drug product. Assay also demonstrated high sensitivity, selectivity and precision.Conclusion: A robust, easy to perform immunogenicity assay was developed and validated for detecting anti-tocilizumab antibodies.
[Box: see text].
Sujet(s)
Anticorps monoclonaux humanisés , Anticorps monoclonaux humanisés/immunologie , Anticorps monoclonaux humanisés/sang , Humains , Anticorps/immunologie , Interleukine-6/sang , Interleukine-6/immunologie , Dosage immunologique/méthodesRÉSUMÉ
Interleukin-6 (IL-6), a multifunctional cytokine, is an attractive therapeutic target for immunological and inflammatory diseases. We investigated the chemical synthesis of IL-6 and its enantiomer (d-IL-6) using a sequential N-to-C native chemical ligation strategy from six peptide segments. Solubilizing Trt-K10 tags improved the intermediate solubility and served as protecting groups during the metal-free desulfurization to facilitate the synthesis of full-length IL-6 protein. Synthetic l-IL-6 and recombinant IL-6 exhibited nearly identical structural and binding properties. The symmetrical binding property of d-IL-6 was also demonstrated by functional analysis using IL-6-binding peptides. The resulting functional d-IL-6 was employed to screen a phage-displayed antibody fragment library, leading to the identification of several d-IL-6-binding single-domain antibodies. This work will contribute to the development of novel, potent IL-6 inhibitors without the adverse effects of undesired immune activation.
Sujet(s)
Interleukine-6 , Interleukine-6/antagonistes et inhibiteurs , Interleukine-6/immunologie , Banque de peptides , Humains , Stéréoisomérie , Peptides/composition chimique , Peptides/synthèse chimique , Protéines recombinantes/composition chimique , Modèles moléculaires , Séquence d'acides aminés , SolubilitéRÉSUMÉ
The fetal development of organs and functions is vulnerable to perturbation by maternal inflammation which may increase susceptibility to disorders after birth. Because it is not well understood how the placenta and fetus respond to acute lung- inflammation, we characterize the response to maternal pulmonary lipopolysaccharide exposure across 24 h in maternal and fetal organs using multi-omics, imaging and integrative analyses. Unlike maternal organs, which mount strong inflammatory immune responses, the placenta upregulates immuno-modulatory genes, in particular the IL-6 signaling suppressor Socs3. Similarly, we observe no immune response in the fetal liver, which instead displays metabolic changes, including increases in lipids containing docosahexaenoic acid, crucial for fetal brain development. The maternal liver and plasma display similar metabolic alterations, potentially increasing bioavailability of docosahexaenoic acid for the mother and fetus. Thus, our integrated temporal analysis shows that systemic inflammation in the mother leads to a metabolic perturbation in the fetus.
Sujet(s)
Foetus , Lipopolysaccharides , Foie , Poumon , Placenta , Femelle , Grossesse , Placenta/métabolisme , Placenta/immunologie , Animaux , Foetus/immunologie , Foetus/métabolisme , Poumon/immunologie , Poumon/métabolisme , Foie/métabolisme , Foie/immunologie , Acide docosahexaénoïque/métabolisme , Protéine-3 suppressive de la signalisation des cytokine/métabolisme , Protéine-3 suppressive de la signalisation des cytokine/génétique , Souris , Inflammation/immunologie , Inflammation/métabolisme , Souris de lignée C57BL , Adaptation physiologique/immunologie , Développement foetal/immunologie , Échange foetomaternel/immunologie , Interleukine-6/métabolisme , Interleukine-6/immunologieRÉSUMÉ
Atractylodes macrocephala Koidz, a traditional Chinese medicine, contains atractylenolide I (ATR-I), which has potential anticancer, anti-inflammatory, and immune-modulating properties. This study evaluated the therapeutic potential of ATR-I for indomethacin (IND)-induced gastric mucosal lesions and its underlying mechanisms. Noticeable improvements were observed in the histological morphology and ultrastructures of the rat gastric mucosa after ATR-I treatment. There was improved blood flow, a significant decrease in the expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-1ß, and IL-18, and a marked increase in prostaglandin E2 (PGE2) expression in ATR-I-treated rats. Furthermore, there was a significant decrease in the mRNA and protein expression levels of NOD-like receptor thermal protein domain associated protein 3 (NLRP3), apoptosis-associated speck-like protein (ASC), cysteinyl aspartate specific proteinase-1 (caspase-1), and nuclear factor-κB (NF-κB) in rats treated with ATR-I. The results show that ATR-I inhibits the NLRP3 inflammasome signaling pathway and effectively alleviates local inflammation, thereby improving the therapeutic outcomes against IND-induced gastric ulcers in rats.
Sujet(s)
Atractylodes , Muqueuse gastrique , Indométacine , Inflammasomes , Lactones , Protéine-3 de la famille des NLR contenant un domaine pyrine , Rat Sprague-Dawley , Sesquiterpènes , Ulcère gastrique , Animaux , Protéine-3 de la famille des NLR contenant un domaine pyrine/métabolisme , Protéine-3 de la famille des NLR contenant un domaine pyrine/génétique , Indométacine/effets indésirables , Ulcère gastrique/traitement médicamenteux , Ulcère gastrique/induit chimiquement , Ulcère gastrique/métabolisme , Rats , Sesquiterpènes/pharmacologie , Sesquiterpènes/composition chimique , Lactones/pharmacologie , Lactones/composition chimique , Inflammasomes/métabolisme , Inflammasomes/génétique , Inflammasomes/effets des médicaments et des substances chimiques , Mâle , Atractylodes/composition chimique , Muqueuse gastrique/effets des médicaments et des substances chimiques , Muqueuse gastrique/métabolisme , Humains , Facteur de transcription NF-kappa B/génétique , Facteur de transcription NF-kappa B/métabolisme , Facteur de transcription NF-kappa B/immunologie , Facteur de nécrose tumorale alpha/génétique , Facteur de nécrose tumorale alpha/métabolisme , Facteur de nécrose tumorale alpha/immunologie , Interleukine-1 bêta/génétique , Interleukine-1 bêta/métabolisme , Interleukine-1 bêta/immunologie , Caspase-1/génétique , Caspase-1/métabolisme , Interleukine-6/génétique , Interleukine-6/métabolisme , Interleukine-6/immunologie , Interleukine-18/génétique , Interleukine-18/métabolismeRÉSUMÉ
Major depressive disorder (MDD) and bipolar disorder (BD) are highly disabling illnesses defined by different psychopathological, neuroimaging, and cognitive profiles. In the last decades, immune dysregulation has received increasing attention as a central factor in the pathophysiology of these disorders. Several aspects of immune dysregulations have been investigated, including, low-grade inflammation cytokines, chemokines, cell populations, gene expression, and markers of both peripheral and central immune activation. Understanding the distinct immune profiles characterizing the two disorders is indeed of crucial importance for differential diagnosis and the implementation of personalized treatment strategies. In this paper, we reviewed the current literature on the dysregulation of the immune response system focusing our attention on studies using inflammatory markers to discriminate between MDD and BD. High heterogeneity characterized the available literature, reflecting the heterogeneity of the disorders. Common alterations in the immune response system include high pro-inflammatory cytokines such as IL-6 and TNF-α. On the contrary, a greater involvement of chemokines and markers associated with innate immunity has been reported in BD together with dynamic changes in T cells with differentiation defects during childhood which normalize in adulthood, whereas classic mediators of immune responses such as IL-4 and IL-10 are present in MDD together with signs of immune-senescence.
Sujet(s)
Trouble bipolaire , Trouble dépressif majeur , Humains , Trouble bipolaire/immunologie , Trouble dépressif majeur/immunologie , Cytokines/immunologie , Médiateurs de l'inflammation/métabolisme , Marqueurs biologiques , Inflammation/immunologie , Interleukine-6/immunologieRÉSUMÉ
The spread of cancer from organ to organ (metastasis) is responsible for the vast majority of cancer deaths; however, most current anti-cancer drugs are designed to arrest or reverse tumor growth without directly addressing disease spread. It was recently discovered that tumor cell-secreted interleukin-6 (IL-6) and interleukin-8 (IL-8) synergize to enhance cancer metastasis in a cell-density dependent manner, and blockade of the IL-6 and IL-8 receptors (IL-6R and IL-8R) with a novel bispecific antibody, BS1, significantly reduced metastatic burden in multiple preclinical mouse models of cancer. Bispecific antibodies (BsAbs), which combine two different antigen-binding sites into one molecule, are a promising modality for drug development due to their enhanced avidity and dual targeting effects. However, while BsAbs have tremendous therapeutic potential, elucidating the mechanisms underlying their binding and inhibition will be critical for maximizing the efficacy of new BsAb treatments. Here, we describe a quantitative, computational model of the BS1 BsAb, exhibiting how modeling multivalent binding provides key insights into antibody affinity and avidity effects and can guide therapeutic design. We present detailed simulations of the monovalent and bivalent binding interactions between different antibody constructs and the IL-6 and IL-8 receptors to establish how antibody properties and system conditions impact the formation of binary (antibody-receptor) and ternary (receptor-antibody-receptor) complexes. Model results demonstrate how the balance of these complex types drives receptor inhibition, providing important and generalizable predictions for effective therapeutic design.
Sujet(s)
Anticorps bispécifiques , Récepteurs à l'interleukine-6 , Récepteurs à l'interleukine-8 , Anticorps bispécifiques/pharmacologie , Anticorps bispécifiques/immunologie , Anticorps bispécifiques/composition chimique , Récepteurs à l'interleukine-6/antagonistes et inhibiteurs , Récepteurs à l'interleukine-6/immunologie , Récepteurs à l'interleukine-6/métabolisme , Humains , Récepteurs à l'interleukine-8/métabolisme , Récepteurs à l'interleukine-8/antagonistes et inhibiteurs , Animaux , Biologie informatique , Simulation numérique , Interleukine-6/métabolisme , Interleukine-6/immunologie , Souris , Interleukine-8/métabolisme , Interleukine-8/immunologie , Interleukine-8/antagonistes et inhibiteurs , Tumeurs/immunologie , Tumeurs/traitement médicamenteuxRÉSUMÉ
The complement component 5a/complement component 5 receptor 1 (C5a/C5aR1) pathway plays a crucial role in the onset and development of inflammation, but relevant studies in fish are lacking. In this study, we successfully characterized the relationship between half-smooth tongue sole (Cynoglossus semilaevis) C5aR1 (CsC5aR1) and bacterial inflammation. First, we showed that the overexpression of CsC5aR1 significantly increased bacterial pathological damage in the liver and intestine, whereas inhibition attenuated the damage. The in vitro experiments suggested that CsC5aR1 was able to positively regulate the phagocytic activity and respiratory burst of tongue sole macrophages. In terms of both transcriptional and translational levels, overexpression/inhibition of CsC5aR1 was followed by a highly consistent up-regulation/decrease of its downstream canonical inflammatory factor interleukin-6 (CsIL-6). Furthermore, we stimulated macrophages by lipopolysaccharide (LPS) and lipoteichoic acid (LTA) and found a broad-spectrum response to bacterial infections by the C5a/C5aR1 complement pathway together with the downstream inflammatory factor CsIL-6. Subsequently, we directly elucidated that CsIL-6 is an indicator of C5a/C5aR1-mediated inflammation at different infection concentrations, different infectious bacteria (Vibrio anguillarum and Mycobacterium marinum), and different detection levels. These results might provide a new inflammation bio-marker for early warning of bacteria-induced hyperinflammation leading to fish mortality and a promising target for the treatment of bacterial inflammation in teleost.
Sujet(s)
Maladies des poissons , Protéines de poisson , Poissons plats , Interleukine-6 , Récepteur à l'anaphylatoxine C5a , Animaux , Poissons plats/immunologie , Poissons plats/génétique , Récepteur à l'anaphylatoxine C5a/génétique , Récepteur à l'anaphylatoxine C5a/immunologie , Maladies des poissons/immunologie , Maladies des poissons/microbiologie , Protéines de poisson/génétique , Protéines de poisson/immunologie , Interleukine-6/génétique , Interleukine-6/immunologie , Interleukine-6/métabolisme , Infections à Vibrio/médecine vétérinaire , Infections à Vibrio/immunologie , Vibrio/physiologie , Inflammation/immunologie , Inflammation/médecine vétérinaire , Régulation de l'expression des gènes/immunologie , Immunité innée/génétiqueRÉSUMÉ
The infection caused by porcine epidemic diarrhea virus (PEDV) is associated with high mortality in piglets worldwide. Host factors involved in the efficient replication of PEDV, however, remain largely unknown. Our recent proteomic study in the virus-host interaction network revealed a significant increase in the accumulation of CALML5 (EF-hand protein calmodulin-like 5) following PEDV infection. A further study unveiled a biphasic increase of CALML5 in 2 and 12 âh after viral infection. Similar trends were observed in the intestines of piglets in the early and late stages of the PEDV challenge. Moreover, CALML5 depletion reduced PEDV mRNA and protein levels, leading to a one-order-of-magnitude decrease in virus titer. At the early stage of PEDV infection, CALML5 affected the endosomal trafficking pathway by regulating the expression of endosomal sorting complex related cellular proteins. CALML5 depletion also suppressed IFN-ß and IL-6 production in the PEDV-infected cells, thereby indicating its involvement in negatively regulating the innate immune response. Our study reveals the biological function of CALML5 in the virology field and offers new insights into the PEDV-host cell interaction.
Sujet(s)
Calmoduline , Endosomes , Immunité innée , Virus de la diarrhée porcine épidémique , Réplication virale , Animaux , Virus de la diarrhée porcine épidémique/immunologie , Virus de la diarrhée porcine épidémique/physiologie , Suidae , Calmoduline/métabolisme , Calmoduline/génétique , Endosomes/métabolisme , Endosomes/virologie , Interactions hôte-pathogène/immunologie , Maladies des porcs/virologie , Maladies des porcs/immunologie , Cellules Vero , Chlorocebus aethiops , Infections à coronavirus/immunologie , Infections à coronavirus/virologie , Infections à coronavirus/médecine vétérinaire , Interleukine-6/génétique , Interleukine-6/métabolisme , Interleukine-6/immunologie , Interféron bêta/génétique , Interféron bêta/immunologie , Interféron bêta/métabolismeRÉSUMÉ
INTRODUCTION: Castleman disease (CD) is a benign lymphoproliferative disease causing severe systemic inflammation. Interleukin-6 (IL-6) is a major pathogenesis of multicentric CD (MCD), but only 30-60% of patients respond to IL-6 inhibitors. Novel agents for IL-6 inhibitor-refractory cases are needed. Clinical data and samples are being collected on a large scale and the clinical, pathological, and pathogenetic aspects are being elucidated. AREAS COVERED: The pathological and clinical classification of CD is outlined. Focusing on idiopathic MCD (iMCD), this review identifies therapeutic targets and summarizes currently recommended drugs and promising therapeutic candidates. EXPERT OPINION: The pathogenesis of MCD has been implicated in the activation of the Janus kinase (JAK)-transcriptional signaling activator (STAT) 3 pathway and the phosphatidylinositol 3-kinase (PI3K)/Akt/mechanical target of rapamycin (mTOR) signaling pathway. iMCD-TAFRO (thrombocytopenia, anasarca, fever/elevated CRP, reticulin myelofibrosis/renal dysfunction, organ enlargement) is resistant to IL-6 inhibitors, and cyclosporine and mTOR inhibitors are sometimes effective. JAK inhibitors and mTOR inhibitors may be therapeutic agents for iMCD. Recently, we have shown that peripheral helper T (Tph) cell abnormalities are at the core of iMCD pathogenesis. Therapies targeting chemokine (C-X-C motif) ligand 13 (CXCL13) produced by Tph cells and blocking the Tph-CXCL13-B cell pathway may satisfy unmet need in refractory cases.
Sujet(s)
Hyperplasie lymphoïde angiofolliculaire , Thérapie moléculaire ciblée , Transduction du signal , Hyperplasie lymphoïde angiofolliculaire/traitement médicamenteux , Hyperplasie lymphoïde angiofolliculaire/immunologie , Humains , Transduction du signal/effets des médicaments et des substances chimiques , Interleukine-6/métabolisme , Interleukine-6/antagonistes et inhibiteurs , Interleukine-6/immunologie , Animaux , Janus kinases/métabolisme , Janus kinases/antagonistes et inhibiteurs , Inhibiteurs des Janus kinases/usage thérapeutique , Sérine-thréonine kinases TOR/antagonistes et inhibiteurs , Sérine-thréonine kinases TOR/métabolismeRÉSUMÉ
The activation of macrophages, essential for the innate defense against invading pathogens, revolves around Toll-like receptors (TLRs). Nevertheless, a comprehensive understanding of the molecular mechanisms governing TLR signaling in the course of macrophage activation remains to be fully clarified. Although Zc3h12c was originally identified as being enriched in organs associated with macrophages, its precise function remains elusive. In this study, we observed a significant induction of Zc3h12c in macrophages following stimulation with TLR agonists and pathogens. Overexpression of Zc3h12c significantly mitigated the release of TNF-α and IL-6 triggered by lipopolysaccharide (LPS), whereas depletion of Zc3h12c increased the production of the cytokines mentioned above. Notably, the expression of IFN-ß was not influenced by Zc3h12c. Luciferase reporter assays revealed that Zc3h12c could suppress the TNF-α promoter activity. Moreover, Zc3h12c exerted a notable inhibitory effect on JNK, ERK, p38, and NF-κB signaling induced by LPS. In summary, the findings of our study suggest that Zc3h12c functions as a robust suppressor of innate immunity, potentially playing a role in the pathogenesis of infectious diseases.
Sujet(s)
Immunité innée , Lipopolysaccharides , Activation des macrophages , Macrophages , Transduction du signal , Facteur de nécrose tumorale alpha , Immunité innée/immunologie , Animaux , Activation des macrophages/immunologie , Souris , Lipopolysaccharides/pharmacologie , Lipopolysaccharides/immunologie , Macrophages/immunologie , Macrophages/métabolisme , Cellules RAW 264.7 , Facteur de nécrose tumorale alpha/métabolisme , Facteur de nécrose tumorale alpha/immunologie , Transduction du signal/immunologie , Facteur de transcription NF-kappa B/métabolisme , Récepteurs de type Toll/métabolisme , Récepteurs de type Toll/immunologie , Humains , Interleukine-6/métabolisme , Interleukine-6/immunologieRÉSUMÉ
Myeloid-derived suppressor cells (MDSCs), the negative immune regulators, have been demonstrated to be involved in immune responses to a variety of pathological conditions, such as tumors, chronic inflammation, and infectious diseases. However, the roles and mechanisms underlying the expansion of MDSCs in malaria remain unclear. In this study, the phenotypic and functional characteristics of splenic MDSCs during Plasmodium yoelii NSM infection are described. Furthermore, we provide compelling evidence that the sera from P. yoelii-infected C57BL/6 mice containing excess IL-6 and granulocyte-macrophage colony-stimulating factor promote the accumulation of MDSCs by inducing Bcl2 expression. Serum-induced MDSCs exert more potent suppressive effects on T cell responses than control MDSCs within both in vivo P. yoelii infection and in vitro serum-treated bone marrow cells experiments. Serum treatment increases the MDSC inhibitory effect, which is dependent on Arg1 expression. Moreover, mechanistic studies reveal that the serum effects are mediated by JAK/STAT3 signaling. By inhibiting STAT3 phosphorylation with the JAK inhibitor JSI-124, effects of serum on MDSCs are almost eliminated. In vivo depletion of MDSCs with anti-Gr-1 or 5-fluorouracil significantly reduces the parasitemia and promotes Th1 immune response in P. yoelii-infected C57BL/6 mice by upregulating IFN-γ expression. In summary, this study indicates that P. yoelii infection facilitates the accumulation and function of MDSCs by upregulating the expression of Bcl2 and Arg1 via JAK/STAT3 signaling pathway in vivo and in vitro. Manipulating the JAK/STAT3 signaling pathway or depleting MDSCs could be promising therapeutic interventions to treat malaria.
Sujet(s)
Janus kinases , Paludisme , Souris de lignée C57BL , Cellules myéloïdes suppressives , Plasmodium yoelii , Facteur de transcription STAT-3 , Transduction du signal , Animaux , Plasmodium yoelii/immunologie , Paludisme/immunologie , Cellules myéloïdes suppressives/immunologie , Souris , Facteur de transcription STAT-3/métabolisme , Transduction du signal/immunologie , Janus kinases/métabolisme , Protéines proto-oncogènes c-bcl-2/métabolisme , Facteur de stimulation des colonies de granulocytes et de macrophages/métabolisme , Arginase/métabolisme , Interleukine-6/métabolisme , Interleukine-6/immunologie , FemelleRÉSUMÉ
Background: Acute immune responses to coronavirus disease 2019 (COVID-19) are influenced by variants, vaccination, and clinical severity. Thus, the outcome of these responses may differ between vaccinated and unvaccinated patients and those with and without COVID-19-related pneumonia. In this study, these differences during infection with the Omicron variant were investigated. Methods: A total of 67 patients (including 47 vaccinated and 20 unvaccinated patients) who were hospitalized within 5 days after COVID-19 symptom onset were enrolled in this prospective observational study. Serum neutralizing activity was evaluated using a pseudotyped virus assay and serum cytokines and chemokines were measured. Circulating follicular helper T cell (cTfh) frequencies were evaluated using flow cytometry. Results: Twenty-five patients developed COVID-19 pneumonia on hospitalization. Although the neutralizing activities against wild-type and Delta variants were higher in the vaccinated group, those against the Omicron variant as well as the frequency of developing pneumonia were comparable between the vaccinated and unvaccinated groups. IL-6 and CXCL10 levels were higher in patients with pneumonia than in those without it, regardless of their vaccination status. Neutralizing activity against the Omicron variant were higher in vaccinated patients with pneumonia than in those without it. Moreover, a distinctive correlation between neutralizing activity against Omicron, IL-6 levels, and cTfh proportions was observed only in vaccinated patients. Conclusions: The present study demonstrates the existence of a characteristic relationship between neutralizing activity against Omicron, IL-6 levels, and cTfh proportions in Omicron breakthrough infection.